class="knockout" style="margin-top: 0px;margin-bottom: 1px;font-size: 14px;line-height: 1.2;padding: 5px;padding-left: 20px;padding-right: 20px;font-weight: normal;">THANK YOU FOR SUBSCRIBING
RootPath, a Cambridge, MA-based biotechnology company developing a robust T cell therapy platform that bridges precision medicine and cancer immunotherapy, announced a $7m seed funding round led by Sequoia China with participation from Volcanics Venture, BV (Baidu Ventures) and Nest. Bio Ventures.
The company will use its proceeds to advance its immuno-oncology programs and obtain critical data on accuracy, efficacy, and safety in animal models.
Check Out : TOP BIOTECH STARTUPS IN UK
Founded in 2017 by Drs. Xi Chen, Le Cong, Yinqing Li and Ely Porter, RootPath develops a personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. It is developing next-generation technologies to precisely monitor, modulate and steer the immune system to innovate the fields of the diagnosis and treatment of cancer. Nest launched the company. Bio Ventures in 2017 and was incubated in Nest. Bio Labs in both Cambridge, Massachusetts and Hangzhou, China.